CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
CRA's Competition & Antitrust Practice commemorates Canada Day
Our Toronto team advises clients on complex antitrust, merger, and regulatory matters in Canada, Europe, and the United States. We would like to take this...